Skip to main content
Midas Edge

MoonLake Immunotherapeutics

For the period ended Mar 31, 2024. Filed May 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

MLTX$12.56-0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Operations

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Three Months Ended March 31,
20242023
Operating expenses
Research and development$(13,014,049)$(7,415,097)
General and administrative(6,806,440)(5,516,469)
Total operating expenses(19,820,489)(12,931,566)
Operating loss(19,820,489)(12,931,566)
Other income, net5,915,220723,589
Loss before income tax(13,905,269)(12,207,977)
Income tax expense(70,252)(11,010)
Net loss$(13,975,521)$(12,218,987)
Of which: net loss attributable to controlling interests shareholders(13,673,656)(9,004,856)
Of which: net loss attributable to noncontrolling interests shareholders(301,865)(3,214,131)
Net unrealized gain on marketable securities and short term investments182,27324,472
Actuarial gain (loss) on employee benefit plans81,230(42,144)
Other comprehensive income (loss)263,503(17,672)
Comprehensive loss$(13,712,018)$(12,236,659)
Comprehensive loss attributable to controlling interests shareholders(13,415,707)(9,017,481)
Comprehensive loss attributable to noncontrolling interests(296,311)(3,219,178)
Weighted-average number of Class A Ordinary Shares, basic and diluted62,637,21239,061,977
Basic and diluted net loss per share attributable to controlling interests shareholders$(0.22)$(0.23)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.